Publication BLAZE-1 - BLAZE-1, Unpublished (2022) (results posted on registry)
Funding: Not reported/unclear
Conflict of interest: *
Blinding: double blinding
Multicenter / USA |
Follow-up duration (days): 85
350/700mg intravenously single dose
|Characteristics of participants|
Mean age : NR
Severity : Mild: n= 354/ Asymptomatic: n=0
Number of vaccinated participants: NR
|In the register|
Percentage of Participants With SARS-CoV-2 Viral Load Greater Than a Prespecified Threshold in Arms 350 mg Bamlanivimab/700 mg Etesevimab and Placebo [ Time Frame: Day 7 ]
|In the report|
Yes. In English
Data-sharing willing stated in the publication:
|Risk of bias
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
This is an unpublished trial whose results have been reported in ClinicalTrials.gov. The trial registry, protocol and statistical analysis plan were used in data extraction and assessment of risk of bias.
This study reports on the phase 3 results of the Bamlanivimab 350 mg and Etesevimab 700 mg arm.
Time to negative conversion and time to clinical improvement outcomes were reported but the HRs do not include the CI.